JAK Inhibitors Promising for Alopecia Areata JAK Inhibitors Promising for Alopecia Areata
Two investigational new drugs are emerging for patients with moderate to severe hair loss, for whom there are currently no reliable treatments.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2018 Category: Consumer Health News Tags: Dermatology News Source Type: news

Alopecia Areata Trial Results, Skin Oncology Top EADV Agenda Alopecia Areata Trial Results, Skin Oncology Top EADV Agenda
Early results from a trial of JAK inhibitors for hair loss will be unveiled at the upcoming dermatology meeting. Specialists will also delve into the adverse skin effects of immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2018 Category: Consumer Health News Tags: Dermatology News Source Type: news

Janus Kinase Inhibitors: Emerging Applications in Dermatology Janus Kinase Inhibitors: Emerging Applications in Dermatology
Learn about the use of Janus kinase inhibitors, which have become promising treatment options for dermatologic conditions such as psoriasis, atopic dermatitis, alopecia areata, vilitigo, and more.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Fecal Transplant Promising Primary Therapy for C diff Fecal Transplant Promising Primary Therapy for C diff
Fecal microbiota transplantation can be used for the first-line treatment of C difficile, and it might also have an effect on neurologic and autoimmune diseases, such as autism and alopecia areata.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 19, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Alopecia Areata
Title: Alopecia AreataCategory: Diseases and ConditionsCreated: 4/30/1999 12:00:00 AMLast Editorial Review: 3/28/2018 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - March 28, 2018 Category: Dermatology Source Type: news

What to eat for thicker hair: These 10 foods will nourish your locks
(Natural News) Strong, shiny, healthy-looking hair is a sign of beauty. That’s why baldness or hair loss – known as alopecia areata – can be a distressing condition. Alopecia areata affects the scalp, which causes patches of hair loss. Alopecia areata affects both men and women. Like any other part of your body, hair needs... (Source: NaturalNews.com)
Source: NaturalNews.com - February 25, 2018 Category: Consumer Health News Source Type: news

Alopecia Areata: Who Gets Screened for Thyroid Disease? Alopecia Areata: Who Gets Screened for Thyroid Disease?
Many children with alopecia areata get screened for thyroid disease. But do they all need to be?CHOP Expert Commentary (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Pediatrics Expert Interview Source Type: news

Thyroid Screening Advised for Some Kids with Alopecia Areata
(MedPage Today) -- Those with atopy, Down syndrome, and familial history may be at increased risk (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 27, 2017 Category: Dermatology Source Type: news

Bullying and quality of life in pediatric alopecia areata - Christensen T, Yang JS, Castelo-Soccio L.
We report survey result... (Source: SafetyLit)
Source: SafetyLit - September 9, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

FDA Lifts Hold on Concert Pharma's Study Testing Hair Loss Drug FDA Lifts Hold on Concert Pharma's Study Testing Hair Loss Drug
Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2017 Category: Consumer Health News Tags: Dermatology News Source Type: news

FDA lifts hold on Concert Pharma's study testing hair loss drug
(Reuters) - Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss. (Source: Reuters: Health)
Source: Reuters: Health - July 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA lifts hold on Concert Pharma's hair loss drug
(Reuters) - Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss. (Source: Reuters: Health)
Source: Reuters: Health - July 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Alopecia Areata: Current Practices vs. New Directions Alopecia Areata: Current Practices vs. New Directions
Many treatments for alopecia areata are available, but none have been validated or are FDA approved. This paper reviews therapies currently under investigation and novel modalities which show promise.American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDA Places Clinical Hold on Concert Pharma's Hair Loss Drug FDA Places Clinical Hold on Concert Pharma's Hair Loss Drug
Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) imposed a clinical hold on a mid-stage trial testing the company's drug to treat alopecia areata.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 18, 2017 Category: Allergy & Immunology Tags: Pharmacist News Source Type: news

FDA places clinical hold on Concert Pharma's hair loss drug
(Reuters) - Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration imposed a clinical hold on a mid-stage trial testing the company's drug to treat alopecia areata, a type of hair loss. (Source: Reuters: Health)
Source: Reuters: Health - May 17, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Concert Pharmaceuticals commences Phase IIa trial to study CTP-543 in alopecia areata
US-based Concert Pharmaceuticals has commenced the Phase IIa clinical trial of CTP-543 to treat patients with moderate-to-severe alopecia areata. (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

How Should Physicians Respond to Latest Alopecia Research? How Should Physicians Respond to Latest Alopecia Research?
Dr Lipper discusses evidence and strategy for treating patients with alopecia areata.Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 17, 2017 Category: Dermatology Tags: Dermatology Viewpoint Source Type: news

Suicide no more likely in men on 5 α-reductase inhibitors
Raised relative risk of self-harm and depression in first 18 months, but small absolute risk Related items fromOnMedica Keeping our focus on suicide prevention Alopecia areata Male baldness raises risk of coronary heart disease Thousands with BPH will benefit from new treatment (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 20, 2017 Category: UK Health Source Type: news

New treatment option shows promise for skin and hair conditions
Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients ’ quality of life and overall health. An emerging treatment option, however, could provide effective therapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 3, 2017 Category: Science Source Type: news

Study defines global burden of skin disease
(University of Colorado Anschutz Medical Campus) A study published today in JAMA Dermatology combines the prevalence of skin diseases around the world with their likelihood of creating disability across the lifespan to define the following 10 most challenging conditions (arranged in order of decreasing 'disability-adjusted life years'): dermatitis, acne, hives, psoriasis, viral skin diseases, fungal skin diseases, scabies, melanoma, pyoderma, cellulitis, non-melanoma skin cancer, decubitus ulcer, and alopecia areata. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2017 Category: Cancer & Oncology Source Type: news

Tofacitinib Shows Promise for Treating Severe Alopecia Areata Tofacitinib Shows Promise for Treating Severe Alopecia Areata
The Janus kinase (JAK) inhibitor tofacitinib shows promise for treating severe alopecia areata and its variants in adults and adolescents, according to two retrospective studies.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 2, 2016 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Drug restores hair growth in patients with alopecia areata
(Columbia University Medical Center) Seventy-five percent of patients with moderate to severe alopecia areata -- an autoimmune disease that causes patchy, and less frequently, total hair loss -- had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 5, 2016 Category: Biology Source Type: news

JAK Inhibitor Drugs Show Promise in Alopecia Areata JAK Inhibitor Drugs Show Promise in Alopecia Areata
Two different JAK inhibitor drugs, ruxolitinib and tofacitinib, have shown promise as a treatment for alopecia areata in small clinical trials.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 28, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Drug shows promise for hair loss condition
Researchers say a bone marrow drug called Ruxolitinib could help patients regrow hair lost due to the autoimmune condition alopecia areata. WCBS-TV's Dr. Max Gomez reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 26, 2016 Category: Consumer Health News Source Type: news

Four-month baldness treatment ruxolitinib helps patients regrow a full head of hair
Three quarters of sufferers of alopecia areata reported significant hair regrowth when taking ruxolitinib, researchers from the Columbia University Medical Center, New York, found. (Source: the Mail online | Health)
Source: the Mail online | Health - September 26, 2016 Category: Consumer Health News Source Type: news

Medical News Today: Alopecia: Hair growth restored with new drug
Clinical trials conducted by Columbia University Medical Center find that JAK inhibitors may trigger hair regrowth in people with alopecia areata. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 26, 2016 Category: Consumer Health News Tags: Dermatology Source Type: news

Drug restores hair growth in patients with alopecia areata
Seventy-five percent of patients with moderate to severe alopecia areata - an autoimmune disease that causes patchy and, less frequently, total hair loss - had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center (CUMC). By the end of treatment, average hair regrowth among the patients was 92 percent. Findings from an open-label clinical trial of 12 patients with alopecia areata were published in the Journal of Clinical Investigation/Insight, (Source: World Pharma News)
Source: World Pharma News - September 23, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Arthritis Drug May Help With Type of Hair Loss
Researchers saw regrowth in patients with the autoimmune disease alopecia areata (Source: WebMD Health)
Source: WebMD Health - September 22, 2016 Category: Consumer Health News Source Type: news

Drug restores hair growth in patients with alopecia areata
Seventy-five percent of patients with an autoimmune disease that causes hair loss had significant hair regrowth after treatment with ruxolitinib, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 22, 2016 Category: Science Source Type: news

Arthritis Drug May Help With Type of Hair Loss
THURSDAY, Sept. 22, 2016 -- For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests. Alopecia areata is an autoimmune disease that causes... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 22, 2016 Category: Journals (General) Source Type: news

Perth model with Alopecia areata shares video of herself without a wig
Lara Kitchen, a 20-year-old model from Perth, was diagnosed with Alopecia areata at 14. She has shared a video of herself without a wig to encourage women to embrace themselves. (Source: the Mail online | Health)
Source: the Mail online | Health - September 9, 2016 Category: Consumer Health News Source Type: news

Tofacitinib clears pediatric alopecia areata in small study
MINNEAPOLIS – The first study to evaluate tofacitinib’s effectiveness at treating severe alopecia areata in the pediatric population found that the janus kinase inhibitor was effective for more than half of the patients, and well tolerated by all. Of a case series of 13 pediatric patients who had... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 13, 2016 Category: Dermatology Source Type: news

[Podcast] Science Signaling Podcast for 2 August 2016: Patient-specific protein complexes
A technique for identifying patient-specific protein complexes reveals altered signaling in T cells from patients with the autoimmune disease alopecia areata. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 3, 2016 Category: Science Authors: Adam G. Schrum Steven C. Neier, Annalisa M. VanHook Source Type: news

Keys to alopecia areata might lie in gut microbiome
SCOTTSDALE, ARIZ. – Wiping out the gut microbiome with antibiotics prevented alopecia areata in a study of mice, providing evidence that the gut microbiome may play a role in alopecia, Dr. James Chen reported at the annual meeting of the Society for Investigative Dermatology. The finding shows... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 8, 2016 Category: Dermatology Source Type: news

JAK inhibitor improves alopecia, with caveats
SCOTTSDALE, ARIZ. – The Janus kinase (JAK) inhibitor tofacitinib dramatically improved several cases of alopecia areata (AA), although some patients relapsed to worse than baseline after completing treatment in a small open label pilot trial. “Regrowth was demonstrated in 11 out of 12 patients on... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 8, 2016 Category: Dermatology Source Type: news

Concert Pharmaceuticals begins Phase l trial of CTP-543 to treat alopecia areata
Clinical stage, biopharmaceutical company Concert Pharmaceuticals has begun a Phase l clinical trial of CTP-543 to treat alopecia areata, an autoimmune disease that results in partial or complete loss of hair on the scalp. (Source: Drug Development Technology)
Source: Drug Development Technology - May 19, 2016 Category: Pharmaceuticals Source Type: news

The Humanity of Science
I know a few things about the responsibility of being a mom to a powerhouse of a daughter who just does not like the word "no." Lola is 11 years old and I suspect world domination will be in her future as well as an alphabetized kitchen cabinet for me and my shoes lined up to within an inch of their life. She is the magic in the mix to all who love her, and aside from being a true force of nature, Lola is also a warrior who battled aggressive Alopecia Areata for over for two years. As we watched her beautiful chestnut hair fall out in clumps on the bathroom floor, she remained focused on the sun in the sky and he...
Source: Science - The Huffington Post - May 16, 2016 Category: Science Source Type: news

Fayetteville Company Raising Funds for Hair Loss Treatment
A Fayetteville company is trying to raise $7 million to treat hair loss. BiologicsMD Inc. raised $400,000 so far, according to its Feb. 8 filing at the U.S Securities & Exchange Commission. The money raised will go toward helping to get regulatory approval of its treatment for hair loss, mainly for people who have alopecia areata, an autoimmune skin disease that causes hair loss on the head and on other parts of the body, said Dr. Rob Gensure, the company’s medical officer. “They have an immune system problem where their immune system attacks their hair follicle, and it falls out in patches at random times,...
Source: Arkansas Business - Health Care - March 7, 2016 Category: American Health Source Type: news

Targeted Treatment May Reverse Alopecia AreataTargeted Treatment May Reverse Alopecia Areata
The psoriasis drug ustekinumab can spur hair regrowth and normalize immune function in patients with alopecia areata, according to the results of a study in three patients. Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 14, 2015 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

A Baldness Cure Isn't Here Yet, But New Research Is Promising
No one is claiming a cure for baldness just yet, but researchers at Columbia University Medical Center may have taken an important step in that direction. In a series of experiments involving mice and human tissue, the scientists showed that enzyme-blocking drugs known as JAK inhibitors can cause significant regrowth of hair when applied to the skin. The unexpected finding raises the possibility that these medications might be used to restore hair growth in men and women experiencing pattern baldness, as well as in cancer patients who have lost hair as a result of chemotherapy treatments. Oral versions of the med...
Source: Science - The Huffington Post - October 27, 2015 Category: Science Source Type: news

What Is Telogen Effluvium?
Discussion Hair is an epidermal appendage. It has a regular cycle of phases where hair grows (anagen), rests (telogen) and has a transition phase (catagen) in between. Normal hair loss is ~50-100 hairs lost/day on the scalp. Normal hair grows about 2.5 mm/week. The history should include details about general health, health stressors especially in last 4-6 months including fevers, surgeries, new medication and life events are important. Review of systems for possible anemia, diabetes, and hypothyroidism and other autoimmune diseases should be obtained including fatigue, constipation, weight changes, night sweats, eye, mus...
Source: PediatricEducation.org - September 21, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Corticosteroids far outpaced minoxidil use for alopecia areata
Alopecia areata sends “hundreds of thousands” of patients to the doctor every year in the United States, and six in ten of those visits end with a corticosteroid prescription, investigators reported in the Journal of Drugs in Dermatology. In contrast, “minoxidil appears either underreported or... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 15, 2015 Category: Dermatology Source Type: news

Researchers beat untreatable eczema with arthritis drug
Researchers have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 20, 2015 Category: Science Source Type: news

WCD: Topical squaric acid may help alopecia areata in kids
VANCOUVER, B.C. – If you haven’t tried topical 5% squaric acid dibutylester for alopecia areata in children, you probably should, according to investigators at the University of Texas in Houston. “We have treated over 500 patients” with decent results. “A lot of children referred to us had failed...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 16, 2015 Category: Dermatology Tags: PED Conferences SAN Conference News PED News PED Dermatology SAN Clinical News SAN News SAN Hair & Nail Disorders FPN News Source Type: news

Alopecia in APS type 3
Makino et al. present a case of autoimmune polyglandular syndrome (APS) type 3 with a severe form of alopecia areata ( 76 – 99% hair loss). Although recovery from alopecia is rare in APS, they found that following successful control of diabetes, the patient had total hair re-growth within 2-3 months. Read full Case Report by Makino et al. titled ‘Recovery from alopecia areata in a patient with autoimmune polyglandular syndrome type 3 ‘ in Endocrinology, Diabetes & Metabolism Case Reports, Article ID: 14-0084; DOI:10.1530/EDM-14-0084 (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 26, 2015 Category: Endocrinology Source Type: news

Combination Therapy Helpful in Refractory AlopeciaCombination Therapy Helpful in Refractory Alopecia
Combination therapy with diphenylcyclopropenone (DPCP) and anthralin is more effective than DPCP alone in patients with chronic extensive alopecia areata (AA), according to Turkish researchers. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 27, 2015 Category: Dermatology Tags: Dermatology News Source Type: news

North Texas Fracking Zone Sees Growing Health Worries
This story was published by The Center for Public Integrity, a nonprofit, nonpartisan investigative news organization in Washington, D.C. DALLAS—Propped up on a hospital bed, Taylor Ishee listened as his mother shared a conviction that choked her up. His rare cancer had a cause, she believes, and it wasn’t genetics. Others in Texas have drawn the same conclusions about their confounding illnesses. Jana DeGrand, who suffered a heart attack and needed both her gallbladder and her appendix removed. Rebecca Williams, fighting off unexplained rashes, sharp headaches and repeated bouts of pneumonia. Maile Bush, who...
Source: Science - The Huffington Post - December 11, 2014 Category: Science Source Type: news

Coping with alopecia: one bride-to-be's story
As if preparing for her wedding hasn't been stressful enough, Keremi Gawade has had to do it while facing the loss of her hair (Source: Telegraph Health)
Source: Telegraph Health - October 17, 2014 Category: Consumer Health News Tags: wedding plan alopecia causes hair-loss alopecia treatment alopecia areata Source Type: news

Vitiligo, Alopecia Affect 1 in 20 Patients With GVHDVitiligo, Alopecia Affect 1 in 20 Patients With GVHD
In patients with chronic graft-vs-host disease (cGvHD), having a female stem cell donor or a female-donor-to-male-recipient sex mismatch is associated with an increased risk of vitiligo and alopecia areata, according to new findings. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 19, 2014 Category: Dermatology Tags: Dermatology News Source Type: news

Study examines vitiligo, alopecia areata and chronic graft vs. host disease
(The JAMA Network Journals) Vitiligo (depigmentation of the skin) and alopecia areata (AA, patchy or complete hair loss) in patients with chronic graft vs. host disease (GvHD) following a stem cell transplant appear to be associated with having a female donor and the sex mismatch of a female donor and male recipient. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2014 Category: Global & Universal Source Type: news